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OBJECTIVES To analyze the differences in the nitric oxide (NO) forming system between neutrophils
obtained from patients during unstable angina (UA) and during acute myocardial infarction
(AMI).
BACKGROUND Neutrophils are involved in the regulation of thrombus formation through the release of active
substances such as NO. Acute myocardial infarction is the result of an occlusive thrombus;
unstable angina is attributed to intermittent thrombus formation.
METHODS We studied 49 patients admitted to hospital within 24 h after the onset of chest pain: 31
experienced AMI and 18 experienced UA. Acute myocardial infarction was defined as CK
greater than two-fold the upper limit of normal value of biochemical laboratory, with
CK-MB 10% total CK. Unstable angina was defined as transient ST segment changes
without significant increases in CK and CK-MB.
RESULTS The amount of NO generated by neutrophils from AMI patients was significantly higher
than that generated by neutrophils from UA patients. Neutrophils from UA and AMI
patients showed low levels of endothelial-like NO synthase protein expression and a marked
expression of the inducible NO synthase (iNOS) isoform. Although neutrophils from patients
during acute coronary syndromes generated high amounts of NO, they did not demonstrate
an increased ability to stimulate cyclic guanosine monophosphate (cGMP) synthesis in
platelets. This lack of activity to release NO by neutrophils from patients during AMI was
unrelated to a defect in the platelet cGMP-forming system; sodium nitroprusside, an
exogenous NO donor, similarly increased cGMP levels in platelets from AMI patients and
healthy donors.
CONCLUSIONS Neutrophils from patients during AMI and UA showed an increased production of NO and
a marked expression of the iNOS isoform. However, NO released from these neutrophils
showed a deficient functionality. These findings could have clinical implications because they
show differences in thrombus growth in patients with UA versus patients with AMI. (J Am
Coll Cardiol 2002;39:818–25) © 2002 by the American College of Cardiology Foundation
Acute coronary syndromes are the result of thrombus
formation within a coronary artery (1,2). In acute myocar-
dial infarction (AMI) there is a complete, long-lasting,
thrombotic occlusion of a coronary artery. Unstable angina
(UA), on the other hand, is attributed to an incomplete or
short-lived thrombotic coronary occlusion. This variability
could be related to different degrees of platelet activation.
The thrombotic arterial event is a multicellular phenom-
enon in which, in addition to platelets, neutrophils and
endothelium are implicated (3,4). Clinical and experimental
models of coronary ischemia have shown the detrimental
role of neutrophils in the progression of myocardial damage
through their ability to generate oxygen-derived free radi-
cals, such as superoxide anion (5,6). Recently, it has been
demonstrated that neutrophils also produce nitric oxide
(NO) (7). Nitric oxide released by neutrophils has been
demonstrated to prevent neutrophil adhesion to vascular
endothelium and to control aggregation and adhesion of
neighboring platelets (8,9).
Nitric oxide is produced by the metabolic conversion of
L-arginine into L-citrulline due to the activity of NO-
synthesizing enzymes (NO synthase, NOS) (10,11). Func-
tional evidence has demonstrated the presence of a consti-
tutive NOS isoform in neutrophils that we have recently
identified as an endothelial-like NOS isoform (eNOS)
(9,12,13). Under inflammatory conditions, several types of
cells, including neutrophils, express a second NOS isoform,
an inducible NOS isoform (iNOS) (14,15). Whereas eNOS
activity generates small amounts of NO for short periods of
time and is coupled to the endothelium-dependent relax-
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ation, iNOS stimulation results in a delayed and prolonged
release of large amounts of NO (10,11).
As mentioned, NO released by neutrophils has been
shown to inhibit the activation of neighboring platelets
through the stimulation of cyclic guanosine monophosphate
(cGMP) formation in platelets (8,16,17). The ability of
neutrophils to produce NO during acute coronary syn-
dromes, however, has not been previously studied. In the
present study we have analyzed the differences between the
NO-forming system in neutrophils obtained from patients
during UA versus in those obtained from patients during
AMI.
MATERIALS AND METHODS
Patients. Forty-nine consecutive patients admitted to the
Coronary Care Unit and Emergency Unit of Fundacio´n
Jime´nez Dı´az were investigated. Of these, 31 had transmu-
ral AMI diagnosed on the basis of the classical criteria of
prolonged chest pain accompanied by serial changes on the
standard 12-lead electrocardiogram (ECG) and raised se-
rum CK (greater than two-fold upper limit of normal value
of biochemical laboratory) and CK-MB (10% total CK).
Eighteen patients had unstable angina diagnosed on the
basis of chest pain at rest and transient ST segment changes,
without significant increases in CK (1.5-fold more than the
upper normal range) and CK-MB. The control group
included 20 healthy volunteers from the hospital staff. The
results obtained from healthy volunteers were only used as
reference for normal values because the aim of the study was
to analyze the differences between the neutrophil NO-
forming system in AMI versus in UA.
The criteria for enrollment were admission within 24 h
after the onset of chest pain. The criteria for exclusion were
a previous episode of acute coronary syndrome or the recent
exposure (during the preceding two weeks) to antithrom-
botic, steroidal and nonsteroidal anti-inflammatory drugs or
heparin. Moreover, the present study did not include
patients or control subjects with a history of neoplastic,
infectious or autoimmune diseases or any surgical procedure
in the preceding six months. The study was performed
between January 1998 and May 2000. All subjects gave fully
informed consent and the study was approved by the Ethics
Committee of Fundacio´n Jime´nez Dı´az.
Blood sampling. Blood samples were drawn from a pe-
ripheral vein on admission. A 20 ml blood sample was
obtained for neutrophil isolation by peripheral venipuncture
with a syringe containing 0.2 ml of EDTA. A further 10 ml
blood sample was also obtained in acid-citrate-dextrose for
platelet-rich plasma (PRP) isolation.
Neutrophil isolation and PRP preparation. Neutrophils
were isolated as previously described (7,8). Isolation and
manipulation of neutrophils were always performed under
sterile conditions. Neutrophils were isolated by Ficoll/
Hypaque centrifugation. Neutrophils (95% pure, 98% viable
by trypan blue exclusion) were resuspended in RPMI 1640
medium supplemented with 0.25% bovine serum albumin, 5
mmol/l glutamine, 2  105 g/l penicillin and 2  105
g/l streptomycin.
Platelet-rich plasma was obtained from the same donor
for each experiment as described (8,17). In brief, blood
samples were collected in acid-citrate-dextrose (10% vol/
vol) and centrifuged at 800 g for 15 min. Platelet-rich
plasma was obtained and platelet number counted by a
coulter counter. The platelet number was adjusted with
platelet-poor plasma obtained from the same individual to
2.5  108 cells/ml plasma.
Determination of [3H]-L-citrulline content. As detailed
elsewhere (8,17), isolated neutrophils were counted and
incubated during 45 min at 37°C in the above-described
RPMI 1640 medium containing 1 Ci/ml [3H]-L-
arginine. Unincorporated [3H]-L-arginine was washed out
twice with the same medium free of [3H]-L-arginine; 3 
106 neutrophils/sample were incubated during 10 min at
37°C.
After incubation, the neutrophils were lysed with cold
ethanol and the supernatants collected and evaporated until
dryness under N2 atmosphere. As previously described (7),
the extracts were resuspended in 20 mmol/l Hepes/KOH,
pH 5.5 and applied to columns of Dowex AG50WX8 (Na
form) which were subsequently eluted with water (L-
citrulline fraction) and 0.5 mol/l NaOH (L-arginine frac-
tion). The [3H]-L-citrulline fraction was quantified by
liquid-scintillation counting. This column method separates
L-arginine from L-citrulline by up to 92  3%.
Determination of eNOS and iNOS protein expression.
Endothelial NO synthase and inducible NO synthase
protein expression were analyzed in human neutrophils
by Western blotting, as previously described (18,19). Neu-
trophils were lysed in Laemmli buffer containing
2-mercaptoethanol (20). Proteins were separated on dena-
turing sodium dodecyl sulfate-10% polyacrylamide gels.
Equal amounts of proteins (10 g/lane) estimated by
bicinchoninic acid reagent (Pierce, Rockford, Illinois) were
loaded in the gel. A parallel gel with identical samples was
run and stained with Commassie to compare the intensities
of the protein bands. The separated proteins were then
blotted into nitrocellulose (Immobilon-P, Millipore Corp.,
Bedford, Massachusetts). Blots were blocked overnight at
4°C with 5% nonfat dry milk in TBS-T (20 mmol/l Tris
[hydroxymethyl] aminomethane [Tris-HCl], 137 mmol/l
NaCl, 0.1% Tween 20). Western blot analysis was per-
Abbreviations and Acronyms
AMI  acute myocardial infarction
cGMP  cyclic guanosine monophosphate
eNOS  endothelial nitric oxide synthase
iNOS  inducible nitric oxide synthase
NO  nitric oxide
PRP  platelet-rich plasma
SOD  superoxide dismutase
UA  unstable angina
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formed with monoclonal antibodies against eNOS or iNOS
proteins (Transduction Laboratories, Lexington, United
Kingdom). We have previously reported that these mono-
clonal antibodies specifically recognized the eNOS and
iNOS isoforms (18,19,21).
Blots were incubated with the first antibody (1:2,500) for
1 h at room temperature and, after extensive washing, with
the second antibody (horseradish peroxidase-conjugated
antimouse immunoglobulin antibody) at a dilution of
1:1,500 for a further 1 h. Specific eNOS protein and iNOS
protein were detected by enhanced chemiluminescence
(ECL, Amersham Iberica, Madrid, Spain) and evaluated by
densitometry (Molecular Dynamics, Sunnyvale, California).
Prestained protein markers were used for molecular mass
determinations.
Measurement of cGMP. The measurement of cGMP was
used as a bioassay of NO functionality. Nitric oxide pro-
duced by neutrophils increases cGMP production in plate-
lets via activation of soluble guanylate cyclase; therefore, the
amount of cGMP in the neutrophil/platelet suspension
could be considered an index of the NO bioactivity. Cyclic
GMP concentrations in the platelet/neutrophil suspension
were determined as previously described (8,19). In brief,
100 l of the neutrophil suspension were added to PRP to
reach a final amount of 1.25  108 platelets and 1  106
neutrophils (125:1), which approximates the relative con-
centrations in normal blood. The suspension of neutrophils
and platelets was incubated for 15 min at 37°C with
continuous stirring (1,000 rpm). Parallel samples of PRP in
the absence of neutrophils were also tested. Both platelets
and neutrophils were always obtained from the same donor.
To stop the incubation, cells were pelleted by centrifugation
(2,500 rpm, 4°C, 5 min). The supernatant was aspirated and
cells were extracted at 4°C with a 49:1 (v/v) mixture of 0.1
mol/l ethanol/HCl. The extracts were evaporated using a
speed vac evaporator (Model VR-1/120/240, Heto Lab-
Equipment A/S, Denmark). Cyclic GMP concentrations
were measured in acetylated samples by means of a radio-
immunoassay kit (Amersham International, Buckingham-
shire, United Kingdom). The sensitivity of the assay was
0.5 fmol. The intra-assay and interassay variations were
8.9% and 16%, respectively.
Neutrophil superoxide radical generation. The amount
of superoxide anion generated by neutrophils was deter-
mined by measuring the superoxide dismutase (SOD) in-
hibitable reduction of ferricytochrome C. In brief, neutro-
phils at a concentration of 3  106 cells/ml were placed in
a water bath at 37°C in the above-described RPMI-1640
medium containing 0.1 mmol/l ferricytochrome C. The
generation of superoxide anion was calculated as the differ-
ence in absorbance between aliquots of cells incubated with
and without SOD 100 g/ml. The difference was then
divided by the molar extinction coefficient change between
ferricytochrome C and ferrocytochrome C to determine
nmoles of superoxide radicals produced by 5  106 neutro-
phils over 20 min. All observations were made in triplicate
and the data averaged. The absorbance was measured in a
spectrophotometer at 550 nm.
Nitrotyrosine protein formation in neutrophils. Under
circumstances where both NO and superoxide are cogener-
ated, they react with each other and yield the harmful
peroxynitrite which has a very short half-life (1.9 s at pH
7.4) (22). However, peroxynitrite reacts with L-tyrosine to
produce nitrotyrosine, which is a stable substance and can be
used as an in vivo marker of peroxynitrite formation. Thus,
we measured the content of nitrotyrosine proteins in neu-
trophils derived from UA and AMI patients by Western
blotting, as mentioned, for eNOS and iNOS protein.
Western blot was developed using a monoclonal antibody
against nitrotyrosine groups (1:200, Calbiochem, San Di-
ego, California) (23).
Statistical methods. Results are expressed as means 
SEM. Unless otherwise stated, each value corresponds to a
duplicate assay of each sample. To determine the statistical
significance, we have performed ANOVA with Bonferroni’s
correction for multiple comparisons or a Student’s t test,
paired or unpaired. A p value 0.05 was considered
statistically significant.
RESULTS
NOS expression and NO generation in neutrophils.
Table 1 shows the clinical features and previous medication
of the UA and AMI patients. The healthy volunteers from
the hospital staff, whose mean age was 42  5 years (range
28 to 52 years), had not ingested any drug for at least two
weeks before the study.
We determined the ability of neutrophils to produce NO
by measuring the accumulation of [3H]-L-citrulline in
[3H]-L-arginine-loaded neutrophils. A significant increase
in the accumulation of [3H]-L-citrulline was found in
neutrophils obtained from patients during AMI compared
with that in patients during UA ([3H]-L-citrulline: AMI:
64  5, UA: 45  6 nmol/min, p  0.05). The amount of





Age (yrs) 70.2  9.9 67.9  13.8
Men/women 12/6 19/12
Risk factors, n (%)
Smoker 4 (22.2%) 12 (38.7%)
Hypertension 11 (61.1%) 17 (54.8%)
Hypercholesterolemia
(total cholesterol 200 mg/dl)
7 (38.9%) 16 (51.6%)
Diabetes mellitus 6 (33.3%) 9 (29.0%)
Previous myocardial syndrome 0 0
Medication on admission, %
-blockers 3 (16.7%) 4 (12.9%)
Calcium antagonists 3 (16.7%) 3 (16.1%)
ACE inhibitors 2 (11.1%) 3 (12.9%)
Diuretics 2 (11.1%) 3 (12.9%)
Nitrates 18 (100%) 31 (100%)
ACE  angiotensin-converting enzyme; AMI  acute myocardial infarction; UA 
unstable angina.
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[3H]-L-citrulline generated by neutrophils from the healthy
volunteers was always lower than that generated by neutro-
phils from patients during the acute coronary syndromes
([3H]-L-citrulline in control neutrophils: 7  2 nmol/min;
p  0.05 with respect to AMI and UA). In the presence of
L-NAME (104 mol/l), the conversion of [3H]-L-arginine
to [3H]-L-citrulline was inhibited by 85  4% in the
neutrophils isolated from any experimental group, indicat-
ing the specificity of the reaction.
Neutrophils from UA and AMI patients showed low
levels of eNOS protein expression (Figs. 1A and 1B), but
they demonstrated a marked iNOS protein expression (Figs.
2A and 2B). Inducible NO synthase protein expression was
almost absent in the neutrophils from control volunteers
(Figs. 2A and 2B), which demonstrated a marked eNOS
protein expression (Figs. 1A and 1B).
cGMP formation in the suspension of platelets and
neutrophils. The antiplatelet effect of cGMP has been
shown to be the main mediator of the cellular effects of NO
(8,16). Therefore, we determined the cGMP levels in
coincubations of platelets and neutrophils as an index of NO
functionality.
Cyclic GMP levels in platelets isolated from acute coro-
nary syndromes were higher than in platelets isolated from
control volunteers (Fig. 3). In this regard, platelets obtained
from AMI patients showed a significant increase in the
content of cGMP compared with platelets obtained from
UA patients (Fig. 3).
When cGMP was measured in the coincubation of
platelets and neutrophils, it was found increased in UA
patients and healthy volunteers with respect to the level
observed in their respective platelets alone (Fig. 3). The
Figure 1. (Top) Representative Western blot demonstrating endothelial nitric oxide synthase (eNOS) expression in human neutrophils obtained from
healthy volunteers (control) and patients during acute myocardial infarction (AMI) and unstable angina (UA). (Bottom) Bar graph showing the
densitometric analysis of the Western blot. Results are presented as mean  SEM. *p  0.05 with respect to neutrophils obtained from healthy donors.
Figure 2. (Top) Representative Western blot demonstrating inducible nitric oxide synthase (iNOS) expression in human neutrophils obtained from healthy
volunteers (control) and patientes during acute myocardial infarction (AMI) and unstable angina (UA). (Bottom) Bar graph showing the densitometric
analysis of the Western blot. Results are presented as mean  SEM. *p  0.05 with respect to neutrophils obtained from healthy donors. **p  0.05 with
respect to neutrophils from UA patients.
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increase in the cGMP levels observed in the presence of
neutrophils from UA patients was very similar to that
obtained in the presence of neutrophils from healthy donors
(cGMP increase: healthy 10 4, UA: 9 2 fmol; pNS).
The increase in cGMP content in the coincubation of
platelets and neutrophils was inhibited by an L-arginine
competitor, 104 mol/l L-NAME (% inhibition: 91 3%),
supporting the involvement of NO.
As shown in Figure 3, the presence of neutrophils from
AMI patients failed to modify the cGMP content with
respect to that measured in platelets alone. Because the
cGMP content in platelets from AMI patients was not
increased by the addition of neutrophils, we analyzed
whether the cGMP generating system in platelets from
these patients could be saturated. We thus determined the
ability of platelets from patients during AMI to generate
cGMP in response to the exogenous NO-donor sodium
nitroprusside (105 mol/l). Sodium nitroprusside increased
the cGMP content in platelets from patients during AMI to
a level similar to that seen in platelets from the healthy
volunteers (cGMP increase: healthy 24  5, AMI 20  3
fmol; p  NS).
Superoxide anion released from neutrophils. As shown
in Figure 4, neutrophils from patients during AMI demon-
strated a significantly higher ability to release superoxide
anion than did neutrophils obtained from either control
volunteers or patients during UA. Although neutrophils
from UA patients tended to release higher amounts of
superoxide anion than those of healthy volunteers, the
difference did not reach statistical significance.
Nitrotyrosine protein formation in neutrophils. Neutro-
phils from patients during an acute coronary syndrome
showed higher levels of nitrotyrosilated proteins than those
from control volunteers (Fig. 5). Three bands with approx-
imate molecular mass of 16, 24, 84 KDa, respectively, were
observed with the antinitrotyrosine antibody. Significant
increased levels of these tyrosine-nitrated proteins were
detected in neutrophils from patients during AMI com-
pared with neutrophils from patients during UA.
DISCUSSION
In the present study, we evaluated the NO-synthesizing
system in a group of patients during an acute coronary
Figure 3. Cyclic guanosine monophosphate (cGMP) levels in platelets and
platelets plus neutrophils obtained from healthy volunteers and patients
during acute coronary syndromes. Determination of cGMP levels were
performed in platelets alone (PLT) or coincubated with neutrophils
(PMN). Platelets and neutrophils were obtained from peripheral blood of
healthy volunteers (control) and patients during unstable angina (UA) and
during acute myocardial infaction (AMI). Results are represented as mean
 SEM. *p  0.05 with respect to the corresponding platelets alone.
Figure 4. Bar graph showing superoxide anion production by neutrophils.
Neutrophils were obtained from control subjects (control), acute myocar-
dial infartion (AMI) and unstable angina (UA) patients. Results are
presented as mean SEM. *p 0.05 with respect to neutrophils obtained
from healthy donors.
Figure 5. (Top) Representative Western blot demonstrating the presence
of nitrotyrosilated proteins in neutrophils from healthy volunteers (control)
and patients during acute myocardial infarction (AMI) and unstable angina
(UA). (Bottom) Bar graph showing the densitometric analysis of the
nitrotyrosilated proteins with apparent molecular weights of 16, 24, 84
KDa that was observed in the Western blot. Results are mean  SEM.
Asterisk  p  0.05 with respect to neutrophils from healthy donor;
star  p  0.05 with respect to neutrophils from UA patients. White
bars  16 KDa; grey bars  24 KDa; black bars  84 KDa.
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syndrome, that is, unstable angina or acute myocardial
infarction. Neutrophils from patients during AMI produced
greater amounts of NO than neutrophils from patients
during UA, but all neutrophils showed an increased ability
to form NO compared with neutrophils from healthy
donors.
eNOS and iNOS expression in neutrophils. Functional
evidence has demonstrated the ability of neutrophils to
produce NO through a constitutively expressed NOS iso-
form (7,9,12). In a previous study, we have identified the
presence of an eNOS-like isoform in human neutrophils
(13). In the present study, we observed that neutrophils
from patients during an acute coronary syndrome showed a
diminished eNOS protein expression compared with neu-
trophils from healthy volunteers.
The mechanisms underlying the downregulation of
eNOS expression in neutrophils from patients during acute
coronary syndromes were not established in the present
study. Although the eNOS isoform had been initially
described as constitutive, in recent years it has been dem-
onstrated that cytokines downregulate eNOS expression in
the endothelium, mesothelium and neutrophils by destabi-
lizing eNOS mRNA (13,24–26). Therefore, the potential
causes for the downregulation of eNOS protein could
include cytokines, which have been reported elevated during
acute coronary syndromes (27–29).
The Western blot experiments also demonstrated that
neutrophils from patients during AMI contained higher
amounts of iNOS protein than neutrophils from patients
during UA. The iNOS isoform has been shown to be
stimulated by the same cytokines that downregulate eNOS
expression (11). The differences observed in the level of
expression of iNOS protein between neutrophils from
patients during UA and during AMI could be related to a
different type and/or different level of cytokines generated
during each specific coronary syndrome. Further studies are
warranted to clarify this issue.
NO activity and cGMP formation. The experiments
related to the level of cGMP in platelets provided a
parameter to determine the biological activity of NO gen-
erated by neutrophils. Whereas neutrophils from UA pa-
tients increased cGMP levels in the platelet/neutrophil
system, neutrophils from AMI patients failed to modify it.
Platelets from patients during acute coronary syndromes
demonstrated higher basal cGMP levels, which could be
attributable not only to the exposure to high levels of NO
but also to the nitrate treatment. The results obtained with
the exogenous NO-donor, sodium nitroprusside, suggested
that there is no defect in the cGMP-forming system in
platelets from AMI. In this regard, the increment in the
cGMP levels observed with sodium nitroprusside stimula-
tion was very similar in platelets from healthy donors and
AMI patients. Taken together, these results could suggest
that the increased generation of NO by neutrophils during
acute coronary syndromes could be accompanied by the
concomitant inactivation of this molecule.
Nitric oxide is catabolized by free radicals and more
particulary by superoxide anion (10). We determined ex vivo
the ability of neutrophils to release superoxide anion.
Neutrophils from AMI patients demonstrated an increased
ability to release superoxide anion, which was associated
with their incapacity to increase cGMP in platelets. Neu-
trophils from UA patients also tended to release higher
amounts of superoxide anion than those from healthy
volunteers; although the difference did not reach statistical
significance, it might be enough to decrease NO activity. In
this regard, it is noteworthy that, although the level of NO
generated by neutrophils from patients during UA was
significantly higher than that generated by neutrophils from
healthy donors, the increase in the cGMP accumulated in
the platelet/neutrophil coincubation was very similar be-
tween them. The measurement of superoxide anion was
based on an in vitro assay and therefore we should interpret
these results with caution. However, these data suggested
the possibility that during acute coronary syndromes the
greater generation of NO by neutrophils could be accom-
panied by an increased catabolism of NO due to the
concomitant release of superoxide radicals. It was further
supported by the fact that the level of nitrotyrosilated
proteins, a marker of peroxynitrite formation, was greater in
neutrophils from patients during acute coronary syndromes.
Interestingly, the different levels of nitrotyrosilated proteins
observed between neutrophils from patients during AMI
and during UA were associated with the different ability of
their neutrophils to increase cGMP formation in their
platelets.
Previous studies in animal models of coronary occlusion
have postulated the involvement of NO in the pathogenesis
of ischemic heart disease. In this regard, Pearson et al. have
reported the impairment of NO-dependent relaxation in
ischemic canine coronary arteries (30). Bauerssachs et al.
(31) have demonstrated that the addition of superoxide
dismutase to isolated coronary arteries from rats with heart
failure partially restored the endothelium-dependent relax-
ation. In the same line of evidences, a substantial reduction
of endothelial SOD and endothelial-mediated dilation in
patients with coronary artery disease has been reported (32).
In this regard, it is also noteworthy that in addition to
serving as a biomarker of peroxynitrite, nitration of tyrosine
residues is known to be an inhibitor of several biochemical
pathways, including SOD (33). However, we have not
performed experiments with superoxide anion scavengers,
such as the mentioned SOD, and therefore the present
study did not allow us to identify whether the production of
superoxide anion is the mechanism responsible for the
deficient activity of the NO released by neutrophils from
patients during acute myocardial infarction.
Nitric oxide produced by neutrophils appears to have a
relevant role in inhibiting platelet activation through cGMP
mediation (8,15). Langford et al. (34) have previously
observed a different degree of platelet activation in patients
with AMI and UA. Moreover, administration of exogenous
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NO-donors reduced platelet P-selectin expression in pa-
tients with acute coronary syndromes (34). Interestingly, it
has been demonstrated that the antioxidant enzyme gluta-
thione peroxidase potentiates the inhibition of platelet
function by NO via the inhibition of reactive oxygen species
(35). There is also evidence that loss of endothelium-
derived NO contributes to the pathogenesis of acute coro-
nary syndromes (36,37). To our knowledge, however the
NO-forming system in neutrophils has not been previously
studied in patients during AMI and UA.
In summary, neutrophils from patients during AMI and
UA showed an increased production of NO and have a
marked expression of the iNOS isoform. However, NO
released from these neutrophils had a deficient functionality
to stimulate cGMP formation by platelets. This fact was
more marked in neutrophils from patients during AMI than
in those from patients during UA. The different function-
ality of the NO released by neutrophils from patients during
UA and AMI could contribute to the different growth of the
thrombus within the coronary vessels and may be a suitable
target for therapy.
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